Discover Guideview's Pharmaceutical articles! Stay informed about the latest news, policies, and scientific insights relevant to the pharmaceutical industry.
Merck Full Year 2025 Financial ReportMerck
Financial statementsMerck's 2025 performance shows 1% revenue growth, driven by strong sales of KEYTRUDA, new products like WINREVAIR, and growth in animal health. The company maintains cautious optimism for 2026 amid challenges like patent cliffs and currency fluctuations.
Eli Lilly Full Year 2025 Financial ReportEli Lilly
Financial statementsEli Lilly's 2025 results show a 45% revenue increase to $65.2B, driven by Mounjaro and Zepbound sales. With strong growth in profits and an optimistic 2026 outlook, the company continues to lead in metabolic diseases and oncology treatments.
Amgen Full Year 2025 Financial ReportAmgen
Financial statementsAmgen's 2025 revenue rose 10%, reaching $36.75B, driven by strong product sales and innovation. The company projects continued growth in 2026, with a focus on R&D, cost control, and shareholder returns.
Pfizer Full Year 2025 Financial ReportPfizer
Financial statementsPfizer’s 2025 financial results show a 2% decline in revenue, driven by lower COVID-19 product sales. Non-COVID products and a strong R&D pipeline drive growth. The company projects steady performance with key catalysts in 2026.
Novo Nordisk Full Year 2025 Financial ReportNovo Nordisk
Financial statementsNovo Nordisk's 2025 report highlights strong revenue growth driven by Wegovy® and Ozempic®, despite challenges in profit margins and rising costs. The company focuses on R&D, sustainability, and managing risks like competition and regulatory pressures.
Daiichi Sankyo Full Year 2025 Financial ReportFinancial statements
Daiichi SankyoDaiichi Sankyo's FY2025 Q3 report highlights $4.4 billion in sales for Enhertu (DS-8201) and significant growth in its ADC portfolio. With groundbreaking treatments and strong pipeline advancements, the company is reshaping the oncology landscape.
Novartis Full Year 2025 Financial ReportFinancial statements
NovartisNovartis' 2025 financial results show strong growth, driven by innovations like Kisqali, Pluvicto, and Leqvio. With a strong pipeline and key market expansions, the company is well-positioned for future growth despite patent challenges.
Roche Full Year 2025 Financial ReportFinancial statements
RocheRoche's 2025 financial results show a 7% sales growth, driven by innovative drugs and diagnostics. Core operating profit rose 13%, with strong performance across key markets. The company remains optimistic for 2026, focusing on sustainable growth.
Lonza Full Year 2025 Financial ReportLonza
Financial statementsLonza reported $7B in revenue for 2025, with its CDMO business driving 70% of growth. Strategic shifts, expanded capacity, and a focus on next-gen therapies like CGT and ADCs position Lonza for continued success in 2026.
Sanofi Full Year 2025 Financial ReportSanofi
Financial statementsSanofi's 2025 results show a 9.9% revenue growth to €43.63 billion, driven by strong sales of Dupixent and new product launches. The company also achieved significant R&D breakthroughs, strategic investments, and continued commitment to sustainability.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
